Display options
Cite
Chimenz R, Chirico V, Cuppari C, et al. Fabry disease and kidney involvement: starting from childhood to understand the future. Pediatr Nephrol. 2021;37(1):95-103doi: 10.1007/s00467-021-05076-x.
Chimenz, R., Chirico, V., Cuppari, C., Ceravolo, G., Concolino, D., Monardo, P., & Lacquaniti, A. (2022). Fabry disease and kidney involvement: starting from childhood to understand the future. Pediatric nephrology (Berlin, Germany), 37(1), 95-103. https://doi.org/10.1007/s00467-021-05076-x
Chimenz, Roberto, et al. "Fabry disease and kidney involvement: starting from childhood to understand the future." Pediatric nephrology (Berlin, Germany) vol. 37,1 (2022): 95-103. doi: https://doi.org/10.1007/s00467-021-05076-x
Chimenz R, Chirico V, Cuppari C, Ceravolo G, Concolino D, Monardo P, Lacquaniti A. Fabry disease and kidney involvement: starting from childhood to understand the future. Pediatr Nephrol. 2022 Jan;37(1):95-103. doi: 10.1007/s00467-021-05076-x. Epub 2021 Apr 30. PMID: 33928440.
Copy Download .nbib Format: NLM
Share it on

Pediatr Nephrol. 2022 Jan;37(1):95-103. doi: 10.1007/s00467-021-05076-x. Epub 2021 Apr 30.

Fabry disease and kidney involvement: starting from childhood to understand the future.

Pediatric nephrology (Berlin, Germany)

Roberto Chimenz, Valeria Chirico, Caterina Cuppari, Giorgia Ceravolo, Daniela Concolino, Paolo Monardo, Antonio Lacquaniti

Affiliations

  1. Pediatric Nephrology and Dialysis Unit, University Hospital "G. Martino", Messina, Italy. [email protected].
  2. Unit of Pediatric Emergency, Department of Adult and Childhood Human Pathology, University Hospital of Messina, Messina, Italy.
  3. Department of Science of Health, Pediatric Unit, Magna Graecia University of Catanzaro, Catanzaro, Italy.
  4. Nephrology and Dialysis Unit, Papardo Hospital, Messina, Italy.

PMID: 33928440 DOI: 10.1007/s00467-021-05076-x

Abstract

The accumulation of globotriaosylceramide (Gb-3) in multiple organs, such as the heart, kidney, and nervous system, due to mutations in the galactosidase alpha (GLA) gene, represents the key point of Fabry disease (FD). The common symptoms appear in childhood or adolescence, including neuropathic pain, angiokeratoma, acroparesthesia, and corneal opacities. A multi-organ involvement induces a significant deterioration in the quality of life with high mortality in adulthood. The accumulation of Gb-3 involves all types of kidney cells beginning at fetal development, many years before clinical manifestations. A decline in the glomerular filtration rate is rare in children, but it can occur during adolescence. Pediatric patients rarely undergo kidney biopsy that could assess the efficacy of enzyme replacement therapy (ERT) behind its diagnostic role. To date, diagnosis is achieved by detecting reduced α-Gal-A activity in leukocytes and plasma, allowing for the early start of ERT. This review focuses on pediatric kidney involvement in FD, analyzing in depth its diagnostic processes and treatment options.

© 2021. IPNA.

Keywords: Children; Enzyme replacement therapy; Fabry disease; Inherited kidney disorder; Kidney biomarkers; Proteinuria

References

  1. Germain DP (2010) Fabry disease. Orphanet J Rare Dis 5:30 - PubMed
  2. Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP, Lemay R, Tylki-Szymanska A, Wilcox WR (2008) Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res 64:550–555 - PubMed
  3. Di Martino MT, Scionti F, Sestito S, Nicoletti A, Arbitrio M, Hiram Guzzi P, Talarico V, Altomare F, Sanseviero MT, Agapito G, Pisani A, Riccio E, Borrelli O, Concolino D, Pensabene L (2016) Genetic variants associated with gastrointestinal symptoms in Fabry disease. Oncotarget 7:85895–85904 - PubMed
  4. Favalli V, Disabella E, Molinaro M, Tagliani M, Scarabotto A, Serio A, Grasso M, Narula N, Giorgianni C, Caspani C, Concardi M, Agozzino M, Giordano C, Smirnova A, Kodama T, Giuliani L, Antoniazzi E, Borroni RG, Vassallo C, Mangione F, Scelsi L, Ghio S, Pellegrini C, Zedde M, Fancellu L, Sechi G, Ganau A, Piga S, Colucci A, Concolino D, Di Mascio MT, Toni D, Diomedi M, Rapezzi C, Biagini E, Marini M, Rasura M, Melis M, Nucera A, Guidetti D, Mancuso M, Scoditti U, Cassini P, Narula J, Tavazzi L, Arbustini E (2016) Genetic screening of Anderson-Fabry disease in probands referred from multispecialty clinics. J Am Coll Cardiol 68:1037–1050 - PubMed
  5. Weidemann F, Sanchez-Niño MD, Politei J, Oliveira JP, Wanner C, Warnock DG, Ortiz A (2013) Fibrosis: a key feature of Fabry disease with potential therapeutic implications. Orphanet J Rare Dis 8:116 - PubMed
  6. Pisani A, Petruzzelli Annicchiarico L, Pellegrino A, Bruzzese D, Feriozzi S, Imbriaco M, Tedeschi E, Cocozza S, De Rosa D, Mignani R, Veroux M, Battaglia Y, Concolino D, Sestito S, Pieruzzi F, Caroti L, Manna R, Zizzo C, Santangelo M, Sabbatini M, Riccio E (2018) Parapelvic cysts, a distinguishing feature of renal Fabry disease. Nephrol Dial Transplant 33:318–323 - PubMed
  7. Germain DP, Charrow J, Desnick RJ, Guffon N, Kempf J, Lachmann RH, Lemay R, Linthorst GE, Packman S, Scott CR, Waldek S, Warnock DG, Weinreb NJ, Wilcox WR (2015) Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet 52:353–358 - PubMed
  8. Hopkin RJ, Jefferies JL, Laney DA, Lawson VH, Mauer M, Taylor MR, Wilcox WR, Fabry Pediatric Expert Panel (2016) The management and treatment of children with Fabry disease: a United States-based perspective. Mol Genet Metab 117:104–113 - PubMed
  9. Scionti F, Di Martino MT, Sestito S, Nicoletti A, Falvo F, Roppa K, Arbitrio M, Guzzi PH, Agapito G, Pisani A, Riccio E, Concolino D, Pensabene L (2017) Genetic variants associated with Fabry disease progression despite enzyme replacement therapy. Oncotarget 8:107558–107564 - PubMed
  10. Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281:249–254 - PubMed
  11. Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, Niezen-Koning KE, van Diggelen OP (1999) The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 105:151–156 - PubMed
  12. Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ (2006) High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 79:31–40 - PubMed
  13. Hopkins PV, Campbell C, Klug T, Rogers S, Raburn-Miller J, Kiesling J (2015) Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri. J Pediatr 166:172–177 - PubMed
  14. Hsu TR, Niu DM (2018) Fabry disease: review and experience during newborn screening. Trends Cardiovasc Med 28:274–281 - PubMed
  15. Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, Eng C, Hopkin RJ, Laney D, Linhart A, Waldek S, Wallace E, Weidemann F, Wilcox WR (2018) Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab 123:416–427 - PubMed
  16. Echevarria L, Benistan K, Toussaint A, Dubourg O, Hagege AA, Eladari D, Jabbour F, Beldjord C, De Mazancourt P, Germain DP (2016) X-chromosome inactivation in female patients with Fabry disease. Clin Genet 89:44–54 - PubMed
  17. Germain DP, Brand E, Burlina A, Cecchi F, Garman SC, Kempf J, Laney DA, Linhart A, Maródi L, Nicholls K, Ortiz A, Pieruzzi F, Shankar SP, Waldek S, Wanner C, Jovanovic A (2018) Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: a multicenter Fabry Registry study. Mol Genet Genomic Med 6:492–503 - PubMed
  18. Lenders M, Weidemann F, Kurschat C, Canaan-Kühl S, Duning T, Stypmann J, Schmitz B, Reiermann S, Krämer J, Blaschke D, Wanner C, Brand SM, Brand E (2016) Alpha-galactosidase A p.A143T, a non-Fabry disease-causing variant. Orphanet J Rare Dis 11:54 - PubMed
  19. Hwu WL, Chien YH, Lee NC, Chiang SC, Dobrovolny R, Huang AC, Yeh HY, Chao MC, Lin SJ, Kitagawa T, Desnick RJ, Hsu LW (2009) Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Hum Mutat 30:1397–1405 - PubMed
  20. van der Tol L, Smid BE, Poorthuis BJ, Biegstraaten M, Deprez RH, Linthorst GE, Hollak CE (2014) A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet 51:1–9 - PubMed
  21. Ramaswami U, Whybra C, Parini R, Pintos-Morell G, Mehta A, Sunder-Plassmann G, Widmer U, Beck M, FOS European Investigators (2006) Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 95:86–92 - PubMed
  22. Vedder AC, Linthorst GE, van Breemen MJ, Groener JE, Bemelman FJ, Strijland A, Mannens MM, Aerts JM, Hollak CE (2007) The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 30:68–78 - PubMed
  23. Pisani A, Visciano B, Imbriaco M, Di Nuzzi A, Mancini A, Marchetiello C, Riccio E (2014) The kidney in Fabry’s disease. Clin Genet 86:301–309 - PubMed
  24. Madsen CV, Granqvist H, Petersen JH, Rasmussen ÅK, Lund AM, Oturai P, Sørensen SS, Feldt-Rasmussen U (2019) Age-related renal function decline in Fabry disease patients on enzyme replacement therapy: a longitudinal cohort study. Nephrol Dial Transplant 34:1525–1533 - PubMed
  25. Chien YH, Olivova P, Zhang XK, Chiang SC, Lee NC, Keutzer J, Hwu WL (2011) Elevation of urinary globotriaosylceramide (GL3) in infants with Fabry disease. Mol Genet Metab 102:57–60 - PubMed
  26. Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, Desnick RJ, O’Callaghan M (2002) Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62:1933–1946 - PubMed
  27. Torra R (2008) Renal manifestations in Fabry disease and therapeutic options. Kidney Int Suppl 111:S29–S32 - PubMed
  28. Hagège A, Réant P, Habib G, Damy T, Barone-Rochette G, Soulat G, Donal E, Germain DP (2019) Fabry disease in cardiology practice: literature review and expert point of view. Arch Cardiovasc Dis 112:278–287 - PubMed
  29. Tøndel C, Kanai T, Larsen KK, Ito S, Politei JM, Warnock DG, Svarstad E (2015) Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria. Nephron 129:1621 - PubMed
  30. Tøndel C, Bostad L, Larsen KK, Hirth A, Vikse BE, Houge G, Svarstad E (2013) Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol 24:137–148 - PubMed
  31. Ramaswami U, Najafian B, Schieppati A, Mauer M, Bichet DG (2010) Assessment of renal pathology and dysfunction in children with Fabry disease. Clin J Am Soc Nephrol 5:365–370 - PubMed
  32. Terryn W, Cochat P, Froissart R, Ortiz A, Pirson Y, Poppe B, Serra A, Van Biesen W, Vanholder R, Wanner C (2013) Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice. Nephrol Dial Transplant 28:505–517 - PubMed
  33. Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, Kanzaki T, Enriquez AL, Eng CM, Tanaka H, Tei C, Desnick RJ (2003) Fabry disease: detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype. Kidney Int 64:801–807 - PubMed
  34. Ichinose M, Nakayama M, Ohashi T, Utsunomiya Y, Kobayashi M, Eto Y (2005) Significance of screening for Fabry disease among male dialysis patients. Clin Exp Nephrol 9:228–232 - PubMed
  35. Cybulla M, Schaefer E, Wendt S, Ling H, Krober SM, Hovelborn U, Schandelmaier S, Rohrbach R, Neumann HP (2005) Chronic renal failure and proteinuria in adulthood: Fabry disease predominantly affecting the kidneys. Am J Kidney Dis 45:82–89 - PubMed
  36. Linthorst GE, Vedder AC, Aerts JMFG, Hollak CEM (2005) Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers. Clin Chim Acta 353:201–203 - PubMed
  37. Auray-Blais C, Millington DS, Barr C, Young SP, Mills K, Clarke JT (2009) Gb(3)/creatinine biomarkers for Fabry disease: issues to consider. Mol Genet Metab 97:237 - PubMed
  38. Bekri S, Lidove O, Jaussaud R, Knebelmann B, Barbey F (2008) The role of ceramide rihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry Disease: a review of the literature. Cardiovasc Hematol Agents Med Chem 4:289–297 - PubMed
  39. Nowak A, Mechtler TP, Desnick RJ, Kasper DC (2017) Plasma LysoGb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes. Mol Genet Metab 120:57–61 - PubMed
  40. Sakuraba H, Togawa T, Tsukimura T, Kato H (2018) Plasma lyso-Gb3: a biomarker for monitoring Fabry patients during enzyme replacement therapy. Clin Exp Nephrol 22:843–849 - PubMed
  41. Chimenz R (2019) Focus on pediatric nephrology. J Biol Regul Homeost Agents 33:1 - PubMed
  42. Sestito S, Falvo F, Sallemi A, Petrisano M, Scuderi MG, Tarsitano F, D’Angelo G, Betta P, Roppa K, Parisi F, Pensabene L, Fede C, Chimenz R, Concolino D (2019) Renal involvement in paediatric Fabry disease. J Biol Regul Homeost Agents 33:59–63 - PubMed
  43. Selvarajah M, Nicholls K, Hewitson TD, Becker GJ (2011) Targeted urine microscopy in Anderson-Fabry disease: a cheap, sensitive and specific diagnostic technique. Nephrol Dial Transplant 26:3195–3202 - PubMed
  44. Nakamichi T, Miyazaki M, Nakayama K, Sato M, Akiu N, Sato T, Sato H, Ito S (2013) Fabry’s disease discovered with chance urinary mulberry cells: a case report. CEN Case Rep 2:49–52 - PubMed
  45. Aoyama Y, Ushio Y, Yokoyama T, Taneda S, Makabe S, Nishida M, Manabe S, Sato M, Kataoka H, Tsuchiya K, Nitta K, Mochizuki T (2020) Urinary Mulberry cells as a biomarker of the efficacy of enzyme replacement therapy for Fabry Disease. Intern Med 59:971–976 - PubMed
  46. Sabino AR, Teixeira Vde P, Nishida SK, Sass N, Mansur JB, Kirsztajn GM (2013) Detection of podocyturia in patients with lupus nephritis. J Bras Nefrol 35:252–258 - PubMed
  47. Mella A, Deambrosis I, Mingozzi S, Colla L, Burdese M, Giaretta F, Bruno S, Camussi G, Boaglio E, Dolla C, Clari R, Biancone L (2020) Detection of urinary podocytes by flow cytometry in idiopathic membranous nephropathy. Sci Rep 10:22379 - PubMed
  48. Liern M, Collazo A, Valencia M, Fainboin A, Isse L, Costales-Collaguazo C, Ochoa F, Vallejo G, Zotta E (2019) Podocyturia in paediatric patients with Fabry disease. Nefrologia 39:177–183 - PubMed
  49. Trimarchi H, Canzonieri R, Schiel A, Politei J, Stern A, Andrews J, Paulero M, Rengel T, Aráoz A, Forrester M, Lombi F, Pomeranz V, Iriarte R, Young P, Muryan A, Zotta E (2016) Podocyturia is significantly elevated in untreated vs treated Fabry adult patients. J Nephrol 29:791–797 - PubMed
  50. Matafora V, Cuccurullo M, Beneduci A, Petrazzuolo O, Simeone A, Anastasio P, Mignani R, Feriozzi S, Pisani A, Comotti C, Bachi A, Capasso G (2015) Early markers of Fabry disease revealed by proteomics. Mol Biosyst 11:1543–1551 - PubMed
  51. Doykov ID, Heywood WE, Nikolaenko V, Śpiewak J, Hällqvist J, Clayton PT, Mills P, Warnock DG, Nowak A, Mills K (2020) Rapid, proteomic urine assay for monitoring progressive organ disease in Fabry disease. J Med Genet 57:38–47 - PubMed
  52. Tebani A, Mauhin W, Abily-Donval L, Lesueur C, Berger MG, Nadjar Y, Berger J, Benveniste O, Lamari F, Laforêt P, Noel E, Marret S, Lidove O, Bekri S (2020) Proteomics-based analysis reveals predictive biological patterns in Fabry Disease. J Clin Med 9:1325 - PubMed
  53. Zhang D, Zhang J, Liang S, Wang J, Liu Z (2018) Clinic-pathologic features and renal outcome of Fabry disease: data from a Chinese cohort. Am J Nephrol 48:137–146 - PubMed
  54. Tøndel C, Bostad L, Hirth A, Svarstad E (2008) Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis 51:767–776 - PubMed
  55. Wijburg FA, Bénichou B, Bichet DG, Clarke LA, Dostalova G, Fainboim A, Fellgiebel A, Forcelini C, An Haack K, Hopkin RJ, Mauer M, Najafian B, Scott CR, Shankar SP, Thurberg BL, Tøndel C, Tylki-Szymańska A, Ramaswami U (2015) Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial. PLoS One 10:e0124987 - PubMed
  56. Desnick RJ (2004) Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval. Expert Opin Biol Ther 4:1167–1176 - PubMed
  57. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ, Fabry Disease Clinical Trial Study Group (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146:77–86 - PubMed
  58. Simoncini C, Chico L, Concolino D, Sestito S, Fancellu L, Boadu W, Sechi GP, Feliciani C, Gnarra M, Zampetti A, Salviati A, Scarpelli M, Orsucci D, Bonuccelli U, Siciliano G, Mancuso M (2016) Mitochondrial DNA haplogroups may influence Fabry disease phenotype. Neurosci Lett 629:58–61 - PubMed
  59. Biegstraaten M, Arngrímsson R, Barbey F, Boks L, Cecchi F, Deegan PB, Feldt-Rasmussen U, Geberhiwot T, Germain DP, Hendriksz C, Hughes DA, Kantola I, Karabul N, Lavery C, Linthorst GE, Mehta A, van de Mheen E, Oliveira JP, Parini R, Ramaswami U, Rudnicki M, Serra A, Sommer C, Sunder-Plassmann G, Svarstad E, Sweeb A, Terryn W, Tylki-Szymanska A, Tøndel C, Vujkovac B, Weidemann F, Wijburg FA, Woolfson P, Hollak CE (2015) Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis 10:36 - PubMed
  60. Arends M, Wijburg FA, Wanner C, Vaz FM, van Kuilenburg ABP, Hughes DA, Biegstraaten M, Mehta A, Hollak CEM, Langeveld M (2017) Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease. Mol Genet Metab 121:157–161 - PubMed
  61. Batista EC, Carvalho LR, Casarini DE, Carmona AK, dos Santos EL, da Silva ED, dos Santos RA, Nakaie CR, Rojas MV, de Oliveira SM, Bader M, D’Almeida V, Martins AM, de Picoly Souza K, Pesquero JB (2010) ACE activity is modulated by the enzyme α-galactosidase A. J Mol Med 89:65–74 - PubMed
  62. Lidove O, West ML, Pintos-Morell G, Reisin R, Nicholls K, Figuera LE, Parini R, Carvalho LR, Kampmann C, Pastores GM, Mehta A (2010) Effects of enzyme replacement therapy in Fabry disease—a comprehensive review of the medical literature. Genet Med 12:668–679 - PubMed
  63. Lenders M, Brand E (2018) Effects of enzyme replacement therapy and antidrug antibodies in patients with Fabry disease. J Am Soc Nephrol 29:2265–2278 - PubMed
  64. Kizhner T, Azulay Y, Hainrichson M, Tekoah Y, Arvatz G, Shulman A, Ruderfer I, Aviezer D, Shaaltiel Y (2015) Characterization of a chemically modified plant cell culture expressed human α-galactosidase-A enzyme for treatment of Fabry disease. Mol Genet Metab 114:259–267 - PubMed
  65. Schiffmann R, Goker-Alpan O, Holida M, Giraldo P, Barisoni L, Colvin RB, Jennette CJ, Maegawa G, Boyadjiev SA, Gonzalez D, Nicholls K, Tuffaha A, Atta MG, Rup B, Charney MR, Paz A, Szlaifer M, Alon S, Brill-Almon E, Chertkoff R, Hughes D (2019) Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: a 1-year Phase 1/2 clinical trial. J Inherit Metab Dis 42:534–544 - PubMed
  66. Kant S, Atta MG (2020) Therapeutic advances in Fabry disease: the future awaits. Biomed Pharmacother 131:110779 - PubMed
  67. Ishii S, Chang HH, Kawasaki K, Yasuda K, Wu HL, Garman SC, Fan JQ (2007) Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin. Biochem J 406:285–295 - PubMed
  68. Feldt-Rasmussen U, Hughes D, Sunder-Plassmann G, Shankar S, Nedd K, Olivotto I, Ortiz D, Ohashi T, Hamazaki T, Skuban N, Yu J, Barth JA, Nicholls K (2020) Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. Mol Genet Metab 131:219–228 - PubMed
  69. Felis A, Whitlow M, Kraus A, Warnock DG, Wallace E (2020) Current and investigational therapeutics for Fabry disease. Kidney Int Rep 5:407–413 - PubMed
  70. Müntze J, Gensler D, Maniuc O, Liu D, Cairns T, Oder D, Hu K, Lorenz K, Frantz S, Wanner C, Nordbeck P (2019) Oral chaperone therapy Migalastat for treating Fabry disease: enzymatic response and serum biomarker changes after 1 year. Clin Pharmacol Ther 105:1224–1233 - PubMed
  71. Simonetta I, Tuttolomondo A, Di Chiara T, Miceli S, Vogiatzis D, Corpora F, Pinto A (2018) Genetics and gene therapy of Anderson-Fabry disease. Curr Gene Ther 18:96–106 - PubMed
  72. Ruiz de Garibay AP, Solinís MA, Rodríguez-Gascón A (2013) Gene therapy for fabry disease: a review of the literature. BioDrugs 27:237–246 - PubMed
  73. Nagree MS, Scalia S, McKillop WM, Medin JA (2019) An update on gene therapy for lysosomal storage disorders. Expert Opin Biol Ther 19:655–670 - PubMed
  74. Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, Goldfarb L, Brady RO, Balow JE, Austin Iii HA, Kopp JB (2002) Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine 81:122–138 - PubMed
  75. Barnes BA, Bergan JJ (1975) Advisory Committee to the Renal Transplant Registry. Renal transplantation in congenital and metabolic diseases. A report from the ASC/NIH Renal Transplant Registry. JAMA 232:148–153 - PubMed
  76. Maizel SE, Simmons RL, Kjellstrand C, Fryd DS (1981) Ten-year experience in renal transplantation for Fabry’s disease. Transplant Proc 13:57–59 - PubMed
  77. Tsakiris D, Simpson HK, Jones EH, Briggs JD, Elinder CG, Mendel S, Piccoli G, dos Santos JP, Tognoni G, Vanrenterghem Y, Valderrabano F (1996) Report on management of renal failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry. Nephrol Dial Transplant 11:4–20 - PubMed
  78. Ojo A, Meier-Kriesche HU, Friedman G, Hanson J, Cibrik D, Leichtman A, Kaplan B (2000) Excellent outcome of renal transplantation in patients with Fabry’s disease. Transplantation 69:2337–2339 - PubMed
  79. Ersözlü S, Desnick RJ, Huynh-Do U, Canaan-Kühl S, Barbey F, Genitsch V, Mueller TF, Cheetham M, Flammer AJ, Schaub S, Nowak A (2018) Long-term outcomes of kidney transplantation in Fabry disease. Transplantation 102:1924–1933 - PubMed
  80. Mignani R, Feriozzi S, Pisani A, Cioni A, Comotti C, Cossu M, Foschi A, Giudicissi A, Gotti E, Lozupone VA, Marchini F, Martinelli F, Bianco F, Panichi V, Procaccini DA, Ragazzoni E, Serra A, Soliani F, Spinelli L, Torti G, Veroux M, Cianciaruso B, Cagnoli L (2008) Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy. Nephrol Dial Transplant 23:1628–1635 - PubMed
  81. Cybulla M, Walter KN, Schwarting A, Divito R, Feriozzi S, Sunder-Plassmann G, European FOS Investigators Group (2009) Kidney transplantation in patients with Fabry disease. Transpl Int 22:475–481 - PubMed
  82. Thadhani R, Wolf M, West ML, Tonelli M, Ruthazer R, Pastores GM, Obrador GT (2002) Patients with Fabry disease on dialysis in the United States. Kidney Int 61:249–255 - PubMed
  83. Cochat P, Fargue S, Mestrallet G, Jungraithmayr T, Koch-Nogueira P, Ranchin B, Zimmerhackl LB (2009) Disease recurrence in pediatric renal transplantation. Pediatr Nephrol 24:2097–2108 - PubMed

Publication Types